作者
Chrysoula Kontogianni, Konstantinos Samitas, Petros Bakakos, Nikolleta Rovina, Stelios Loukides, Andrianna Papaioannou, Nikolaos Tzanakis, Katerina Antoniou, Katerina Dimakou, Georgios Hillas, Sofia Koukidou, Aikaterini-Ioanna Sakellaropoulou, Konstantinos Katsoulis, Maria Kipourou, Niki Georgatou, Dimosthenis Papapetrou, Ourania Kotsiou, Nikolaos Zias, Evangelia Fouka, Konstantinos Porpodis, Maria Hatzimitrova, Despoina Papakosta, Paschalis Steiropoulos, Konstantinos Kostikas, Athena Gogali, Agapi Aggelopoulou, Konstantinos Tatsis, Ilias Papanikolaou, Eleftheria Chaini, Miltiadis Markatos, Stelios Vittorakis, Pantelis Avarlis, Eleni Gaki, Dimitrios Latsios, Eleni Tzortzaki, Eleftherios Zervas
发表日期
2023/9/9
来源
European Respiratory Journal
卷号
62
期号
suppl 67
出版商
European Respiratory Society
简介
Introduction: Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor (IL-5a) that is expressed on eosinophils and inhibits eosinophilic inflammation. It is approved for the treatment of severe eosinophilic asthma.
Aim: To evaluate the clinical experience, effectiveness and safety of benralizumab treatment to patients with severe eosinophilic asthma in Greece.
Methods: A multicenter prospective observational study which was conducted in 19 different Pulmonary Centers in Greece. The recruitment period lasted 18 months and the follow-up period is 2 years.
Preliminary results: 122 patients were eligible (70 women), with an average age of 56 years (min 30, max 82). 76 patients completed the 12month follow up. Significant improvement in ACT score (22±3.5 vs 15.9±4.4, p<0,01) and in FEV1 %pred (81.2±20 vs 72.4±22.2, p<0,01) was observed. There was 77,8% (p<0,001) reduction in …
学术搜索中的文章
C Kontogianni, K Samitas, P Bakakos, N Rovina… - 2023